RTP Mobile Logo
Colorectal Cancer Update, Issue 1, 2018 (Video Program)
Released February 2018

Proceedings from video interviews with Drs Alan P Venook, Scott Kopetz, Zev Wainberg and Howard S Hochster on the treatment of colorectal cancer. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, hematologists-oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of gastrointestinal cancers.

    OVERVIEW OF ACTIVITY
    Approximately 135,000 people were diagnosed with colon or rectal cancer in the United States in 2017 alone, with nearly 50,000 of these individuals succumbing to their disease. Published results from ongoing trials continually lead to the emergence of new therapeutic targets and regimens, thereby altering existing management algorithms. In order to offer optimal patient care, including the option of clinical trial participation, the practicing medical oncologist must be well informed of these advances. To bridge the gap between research and patient care, Colorectal Cancer Update uses one-on-one discussion with leading gastrointestinal oncology investigators. By providing access to the latest scientific developments and the perspectives of experts in the field, this CME activity assists medical oncologists with the formulation of up-to-date management strategies.

    LEARNING OBJECTIVES

    • Formulate an individualized approach to the selection of adjuvant chemotherapy regimens and the duration of treatment for patients with standard- and high-risk colon cancer.
    • Consider patient and disease characteristics in selecting therapy for patients with metastatic colorectal cancer (mCRC), including primary tumor location and presence of potentially targetable genetic abnormalities (eg, BRAF, HER2).
    • Appraise the recent approvals of pembrolizumab and nivolumab for patients with microsatellite instability-high or mismatch repair-deficient tumors, and integrate these agents into current mCRC treatment algorithms.
    • Devise a rational approach to the incorporation of regorafenib and TAS-102 into the treatment algorithm for mCRC that includes consideration of each agent’s unique side-effect profile.
    • Counsel patients regarding the incidence and manifestation of side effects associated with commonly used systemic agents and regimens, and develop a plan to optimally manage these toxicities.
    • Recall available and emerging data with other investigational agents currently being tested in clinical trials for CRC, and refer eligible patients for trial participation or expanded access programs.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/CCU118/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/CCU118.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Alan P Venook, MD
    Professor of Clinical Medicine
    University of California, San Francisco
    San Francisco, California

    Advisory Committee: Bayer HealthCare Pharmaceuticals, Genentech BioOncology; Contracted Research: Bristol-Myers Squibb Company, Genentech BioOncology, Merck, Taiho Oncology Inc.

    Scott Kopetz, MD, PhD
    Associate Professor, Department of Gastrointestinal Medical Oncology
    Division of Cancer Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Consulting Agreements: Amgen Inc, Bayer HealthCare Pharmaceuticals, Genentech BioOncology.

    Zev Wainberg, MD, MSc
    Associate Professor, Department of Medicine
    Director, Early Phase Clinical Research Support
    Co-Director, UCLA GI Oncology Program
    Jonsson Comprehensive Cancer Center
    Los Angeles, California

    Advisory Committee: Genentech BioOncology, Lilly, Merck, Novartis; Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Lilly, Merck, Novartis.

    Howard S Hochster, MD
    Associate Director (Clinical Research)
    Yale Cancer Center
    Professor of Medicine
    Yale School of Medicine
    New Haven, Connecticut

    Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genomic Health Inc.

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Genentech BioOncology, Lilly, Merck and Taiho Oncology Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    nternet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: February 2018
    Expiration date: February 2019

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):

Interview with Alan P Venook, MD

Interview with Scott Kopetz, MD, PhD

Interview with Zev Wainberg, MD, MSc

Interview with Howard S Hochster, MD

Select Publications